If you are interested in external control arms in clinical trials and related topics, come join us Mon afternoon!

Special talk this afternoon- The inaugural Felix Feng Visiting Professorship. Dr. Paul Nguyen did phenomenal job highlighting the impact Felix had on so many of us.

NEW: A novel tool predicts long-term risk of dying from #ProstateCancer, helping doctors interpret PSA results more accurately. Tested on over 200K men, it could help doctors tailor screening and treatment to individual risk and life expectancy. Read now: bit.ly/4pHyUwz @stensy @wandering_gu @UMichUrology #Cancer #CancerScreening

Enhance your expertise in public health with our Summer Session in Epidemiology. Online from July 7-25, you'll gain skills in design and analysis of clinical trials from Dr. Matthew Schipper @StatMatt9 @umichsph

Interesting timely article from @statnews statnews.com/2025/06/06/us-u…

Congratulations to Matt Schipper (@StatMatt9) for winning the @UMich Research Faculty Mentor Award. Matt has a tremendous record of supporting and training dozens of students, staff, trainees, and faculty, so this is very well-deserved! @UMichRadOnc @UMRogelCancer @MichRadOncRes

jamanetwork.com/journals/jam… Nice editorial about 'skimming' the median - 1 number will not fully capture difference between 2 curves.

A study from the @VAAnnArbor provides more data on the impact of lung cancer screening, this time evaluating the survival of a cohort of >2,000 screen-detected lung cancers. acsjournals.onlinelibrary.wi…

It is with profound sadness that we mourn the passing of Felix Feng—an incredible father, husband, UCSF leader, pioneering scientist, entrepreneur, mentor, and cherished friend. Felix’s enduring kindness, brilliant mind, generous spirit, and transformative work in prostate cancer research have touched and saved countless lives. His legacy of compassion, innovation, and excellence will continue to inspire us all. My deepest condolences to Mary, Eric, & Emily during this heartbreaking time. May the One who brings Peace bring Peace to All.💔

Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study Out on Lancet Oncology This retrospective cohort study aimed to evaluate the effectiveness and safety of immune checkpoint inhibitors (ICIs) in Black patients, who were underrepresented in clinical trials leading to ICIs’ approval. Using data from the U.S. Veterans Health Administration, the study included 26,398 patients, of whom 18.7% were Black and 81.3% were White. Results showed that Black patients had a longer time to treatment discontinuation, similar time to next treatment, and slightly improved overall survival compared to White patients. Additionally, Black patients experienced significantly fewer immune-related adverse events, including lower risks of colitis and thyroid issues. These findings suggest that Black patients may have a more favorable therapeutic ratio for ICI treatment, though further investigation is needed to assess the generalizability of these results. @StatMatt9 @garthstrohbehn @DariaBrinzevich @KamyaSankar buff.ly/4fBgtpa

@UMichRadOnc is hiring! We have positions in both GU and Breast and are looking for enthusiastic candidates to apply and join an amazing team of clinicians, physicists, and biologists! #GoBlue. #theteam @ARRO_org @ASTRO_org @ACRORadOnc

Fantastic work, @MLE_Alger, on presenting your first PhD paper @eClinicalMed! rb.gy/7xumij Appreciate the great collaboration with our brilliant multidisciplinary co-authors @Anna_Minchom @lee_1881 @StatMatt9. Keep up the amazing work! 👏 @ICR_CTSU

🌟 Introducing the Weiser Center for Prostate Cancer 🌟 A new era in #prostatecancer care begins at University of Michigan. Our mission: innovation, compassion, and #patientcenteredcare. Discover how: 🔗weiserprostatecancer.org youtube.com/watch?v=pX33Hj5P… 📽️

Excited to share our work showing the first validation of surrogate endpoints in HPV oropharyngeal cancer! We show that LRPFS, DMFS, and PFS correlate with 5yr OS. Important for trial design in this evolving dx space @MierzwaMichelle @StatMatt9 @NRGonc sciencedirect.com/science/ar…

Currently in the midst of a productive meeting with the @MROQC1 consortium, focused on enhancing the quality of radiation treatment across Michigan. #lungcancer @UMichRadOnc @UMRogelCancer

Meet our instructors for the Clinical Epidemiology Cluster! EPID 716: Clinical Epidemiology & Evidenced-Based Research being taught by Dr. Caroline Thompson and EPID 717: Design and Analysis of Clinical Trials is being taught by @StatMatt9. Learn more at: myumi.ch/G1bbn

Four decades of clinical trials: 14.2 million life-years gained, at $326 per year medicalxpress.com/news/2022-…

Dinner with best lab group ever!

Censorship is not the answer.

👇yes! Over and over!